Literature DB >> 24188865

Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy.

M V Maraldo1, N P Brodin2, M C Aznar3, I R Vogelius2, P Munck Af Rosenschöld3, P M Petersen4, L Specht4.   

Abstract

PURPOSE: To evaluate dose plans for head and neck organs at risk (OARs) for classical Hodgkin lymphoma (HL) patients using involved node radiotherapy (INRT) delivered as 3D conformal radiotherapy (3DCRT), volumetric modulated arc therapy (VMAT), and intensity modulated proton therapy (PT), in comparison to the past mantle field (MF).
MATERIALS AND METHODS: Data from 37 patients with cervical lymph node involvement were used. All patients originally received chemotherapy followed by 3DCRT-INRT (30.6 Gy). A VMAT-INRT, PT-INRT (both 30.6 Gy), and a MF plan (36 Gy) were simulated. Doses to head and neck OARs were compared with cumulative DVHs and repeated measures ANOVA.
RESULTS: The estimated median mean doses were 15.3, 19.3, 15.4, and 37.3 Gy (thyroid), 10.9, 12.0, 7.9, and 34.5 Gy (neck muscles), 2.3, 11.1, 1.8, and 37.1 Gy (larynx), 1.7, 5.1, 1.3, and 23.8 Gy (pharynx), 0.5, 0.8, 0.01, and 32.3 Gy (ipsilateral parotid), and 2.4, 3.8, 0.7, and 34.7 Gy (ipsilateral submandibular) with 3DCRT, VMAT, PT, and MF (all p<0.0001), respectively.
CONCLUSION: The use of INRT significantly lowered the estimated radiation dose to the head and neck OARs. VMAT appeared suboptimal compared to 3DCRT and PT, and for some patients, PT offered an additional gain.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  3DCRT; Hodgkin lymphoma; Normal tissues; Proton therapy; Radiotherapy; VMAT

Mesh:

Year:  2013        PMID: 24188865     DOI: 10.1016/j.radonc.2013.09.027

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

Review 1.  The concept and evolution of involved site radiation therapy for lymphoma.

Authors:  Lena Specht; Joachim Yahalom
Journal:  Int J Clin Oncol       Date:  2015-07-07       Impact factor: 3.402

Review 2.  Proton therapy for Hodgkin lymphoma.

Authors:  Michael S Rutenberg; Stella Flampouri; Bradford S Hoppe
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

3.  Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines.

Authors:  Bouthaina Shbib Dabaja; Bradford S Hoppe; John P Plastaras; Wayne Newhauser; Katerina Rosolova; Stella Flampouri; Radhe Mohan; N George Mikhaeel; Youlia Kirova; Lena Specht; Joachim Yahalom
Journal:  Blood       Date:  2018-08-14       Impact factor: 22.113

4.  Proton Therapy For Lymphomas: Current State Of The Art.

Authors:  Umberto Ricardi; Maja V Maraldo; Mario Levis; Rahul R Parikh
Journal:  Onco Targets Ther       Date:  2019-10-01       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.